Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamibarotene - Syros Pharmaceuticals

Drug Profile

Tamibarotene - Syros Pharmaceuticals

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208

Latest Information Update: 17 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; GNI; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia
  • No development reported Neutropenia; Solid tumours
  • Discontinued Breast cancer; Crohn's disease; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 17 Jan 2019 Discontinued - Phase-II for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in France (PO) (Syros Pharmaceuticals pipeline, January 2019)
  • 17 Jan 2019 Discontinued - Phase-II for Acute myeloid leukaemia (First-line therapy, Newly diagnosed) in France (PO) (Syros Pharmaceuticals pipeline, January 2019)
  • 17 Jan 2019 Discontinued - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in France (PO) (Syros Pharmaceuticals pipeline, January 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top